S
Sandra E. Ghayad
Researcher at Lebanese University
Publications - 32
Citations - 1423
Sandra E. Ghayad is an academic researcher from Lebanese University. The author has contributed to research in topics: Rhabdomyosarcoma & Cancer. The author has an hindex of 14, co-authored 27 publications receiving 1172 citations. Previous affiliations of Sandra E. Ghayad include American University of Beirut & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
p53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer
Virginie Marcel,Virginie Marcel,Sandra E. Ghayad,Sandra E. Ghayad,Stephane Belin,Stephane Belin,Gabriel Therizols,Gabriel Therizols,Anne Pierre Morel,Anne Pierre Morel,Eduardo Solano-Gonzàlez,Julie A. Vendrell,Sabine Hacot,Sabine Hacot,Hichem C. Mertani,Hichem C. Mertani,Marie Alexandra Albaret,Marie Alexandra Albaret,Jean-Christophe Bourdon,Lee B. Jordan,Alastair M. Thompson,Yasmine Tafer,Yasmine Tafer,Rong Cong,Philippe Bouvet,Jean Christophe Saurin,Jean Christophe Saurin,Frédéric Catez,Frédéric Catez,Anne-Catherine Prats,Alain Puisieux,Alain Puisieux,Jean-Jacques Diaz,Jean-Jacques Diaz +33 more
TL;DR: It is shown that p53 represses expression of the rRNA methyl-transferase fibrillarin (FBL) by binding directly to FBL, and acts as a safeguard of protein synthesis by regulating FBL and the subsequent quality and intrinsic activity of ribosomes.
Journal ArticleDOI
Evidence for rRNA 2'-O-methylation plasticity: Control of intrinsic translational capabilities of human ribosomes.
Jenny Erales,Virginie Marchand,Baptiste Panthu,Baptiste Panthu,Sandra Gillot,Stephane Belin,Sandra E. Ghayad,Maxime Garcia,Florian Laforêts,Virginie Marcel,Agnès Baudin-Baillieu,Pierre Bertin,Yohann Couté,Annie Adrait,Melanie Meyer,Gabriel Therizols,Marat Yusupov,Olivier Namy,Théophile Ohlmann,Théophile Ohlmann,Yuri Motorin,Frédéric Catez,Jean-Jacques Diaz +22 more
TL;DR: It is revealed that ribosomal RNA 2′-O-methylation can be modulated in human ribosomes, including at key functional sites for translation, and that changes in the 2′'-O- methylation pattern control the intrinsic capabilities of ribosome to translate mRNAs.
Journal ArticleDOI
Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
TL;DR: This review provides an overview of the most recent patents, of pre-clinical and clinical studies of inhibitors targeting the different members and/or activators of the PI3K/Akt/mTOR pathway, used alone or in combination with other targeted agents for the treatment of breast cancer.
Journal ArticleDOI
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Sandra E. Ghayad,Julie A. Vendrell,Sabrina Ben Larbi,Charles Dumontet,Ivan Bièche,Pascale A. Cohen +5 more
TL;DR: In conclusion, the combination of MAPK and PI3K inhibitors represents a promising strategy to overcome endocrine therapy resistance in ER+ breast cancer patients.
Journal ArticleDOI
ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion.
Julie A. Vendrell,Aurélie Thollet,Nhan Trung Nguyen,Sandra E. Ghayad,Stéphanie Vinot,Ivan Bièche,Evelyne Grisard,Véronique Josserand,Jean-Luc Coll,Pierre Roux,Laura Corbo,Isabelle Treilleux,Ruth Rimokh,Pascale A. Cohen +13 more
TL;DR: Findings indicate that ZNF217 mRNA expression may represent a novel prognostic biomarker in breast cancer and therapeutic targeting of Z NF217 of the TGF-β signaling pathway may benefit the subset of patients whose tumors express high levels of ZNF 217.